Researchers with the University of Colorado clinically investigated Longvida's ability to improve vascular endothelial function, as assessed by endothelium dependent dilation (EDD), in middle-aged and older adults. After 12 weeks of 2000mg per day of Longvida® supplementation brachial artery flow-mediated dilation (FMDba) was increased by 36% versus placebo, which showed no change. Results, published in January 2017, indicate that Longvida improves vascular endothelial function by increasing nitric oxide bioavailability through a reduction in oxidative stress and inflammatory signaling in middle-aged and older adults. According to the authors, these results support evidence that supplementation of Longvida may be a promising therapeutic option to improve vascular health. Further, this clinical provides additional support for Longvida’s efficacious ability to promote healthy aging.
Longvida® contains the natural antioxidant curcumin, optimised for maximum bioavailability into blood and target tissues. Longvida® has been extensively studied for various health applications, including nervous system support, promotion of longevity, healthy aging and cognitive health.
Download the complete study on this page and learn more.
Longvida® is a registered trademark of Verdure Sciences. US Patent 9192644, EU Patent 1993365, additional patents pending and it is distributed in Europe by Gee Lawson, division of LEHVOSS UK.